10-Q: The Greater Cannabis Company Reports First Quarter 2024 Results with Continued Net Losses

The Greater Cannabis Company reported no revenue and a net loss of $44,611 for the first quarter of 2024, with ongoing concerns about its ability to continue as a going concern.

Summary

• The Greater Cannabis Company reported its financial results for the first quarter of 2024, showing no revenue from product sales or consulting fees.
• The company incurred a net loss of $44,611 for the quarter, slightly higher than the $43,068 loss in the same period of 2023.
• Operating expenses were $38,951, a slight decrease from $39,468 in the first quarter of 2023.
• The company's cash balance decreased from $166,859 at the end of 2023 to $129,323 by the end of March 2024.
• The company has outstanding notes payable to third parties totaling $171,437.
• There is substantial doubt about the company's ability to continue as a going concern through March 2025 due to negative cash flows and insufficient capital.

Sentiment

Score: 2

Explanation: The document presents a very negative outlook due to the lack of revenue, continued losses, decreasing cash balance, and substantial doubt about the company's ability to continue as a going concern. The company's reliance on external financing and the identified material weaknesses in internal controls further contribute to the negative sentiment.

Negatives

• The company reported no revenue for the first quarter of 2024.
• The company experienced a net loss of $44,611 for the quarter.
• The company's cash balance decreased by $37,536 during the quarter.
• The company has substantial doubt about its ability to continue as a going concern.

Risks

• The company faces the risk of not being able to remediate material weaknesses in internal controls.
• There is a risk that the company may fail to meet the requirements of agreements under which it acquired business interests.
• The company may be unable to secure additional financing to sustain its growth plans.
• The company faces risks related to attracting and retaining qualified personnel.
• The company's profitability is uncertain due to its history of losses.
• There is a risk of failure to obtain adequate financing on a timely basis.
• The company faces risks related to environmental regulation and tax assessments.

Future Outlook

The company plans to conduct clinical studies on and commercialize a cannabinoid-based therapeutic and concentrate on cannabis-related investment and development opportunities. The clinical studies are expected to require an investment of up to $1,000,000 and up to two years to finalize.

Management Comments

• Management is responsible for establishing and maintaining adequate internal control over financial reporting.
• Management has determined that, as of March 31, 2022, the company's internal controls over financial reporting were not effective.

Industry Context

The company is operating in the cannabis industry, which is characterized by rapid changes in regulations and market conditions. The company's focus on cannabinoid therapeutics aligns with a growing interest in the medical applications of cannabis.

Comparison to Industry Standards

• The company's lack of revenue is concerning compared to other companies in the cannabis industry, many of which are generating revenue from product sales or licensing agreements.
• The company's ongoing losses and negative cash flow are also a concern, as many cannabis companies are working towards profitability.
• The company's focus on clinical studies is similar to some other companies in the industry that are pursuing pharmaceutical applications of cannabis, such as GW Pharmaceuticals (now part of Jazz Pharmaceuticals) which developed Epidiolex.
• The company's reliance on external financing is a common challenge for early-stage cannabis companies, but the company's current financial position raises concerns about its ability to secure additional funding.

Related Party Transactions

• Loans payable to related parties include $180,000 from Elisha Kalfa and Yonah Kalfa and $80,000 from Fernando Bisker and Sigalush, LLC.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the substantial doubt about its ability to continue as a going concern.
• Employees may be impacted by potential layoffs or restructuring if the company is unable to secure additional funding.
• Customers and suppliers may be affected by the company's uncertain future and potential cessation of operations.
• Creditors face the risk of not being repaid if the company is unable to generate sufficient revenue or secure additional financing.

Next Steps

• The company plans to conduct clinical studies on its cannabinoid-based therapeutic.
• The company intends to concentrate on cannabis-related investment and development opportunities.
• The company needs to secure additional funding to continue operations.

Key Dates

Keywords

cannabis, financial results, net loss, going concern, cannabinoid therapeutics, clinical studies, financing, operating expenses, internal controls